Neutralizing Antibodies and their Role in Health and Disease

$160.00$240.00

Chenguang Shen – School of Public Health, Zhujiang Hospital, Southern Medical University, China
Yang Yang – Shenzhen Key Laboratory of Pathogen and Immunity, National Clinical Research Center for Infectious Disease, State Key Discipline of Infectious Disease, Shenzhen Third People’s Hospital, Shenzhen, China
Minghui Yang – Advanced Research Institute of Multidisciplinary Science, Beijing Institute of Technology, Beijing, China

Series: Immunology and Immune System Disorders
BISAC: MED044000
DOI: https://doi.org/10.52305/CJKN3850

As of July 2023, 209 monoclonal antibody drugs have been approved by the FDA for marketing use, which are widely distributed in the fight against immune diseases, infectious diseases, and neurological and metabolic diseases. In this book, we introduce current monoclonal drug development techniques, delivery and therapeutic application of neutralizing antibodies, development and application of anti-inflammatory factor monoclonal antibodies, research progress and prospect of monoclonal antibodies against human infectious diseases (including SARS-CoV-2, Enterovirus, Herpesvirus, Hepatitis Virus, and Orthopoxvirus), and the research and applications of nanobodies in human infectious diseases. Most of the content of this book is aimed at viral infectious diseases that are widespread and seriously endanger human health. For example, SARS-CoV-2 continues to circulate the world. Enteroviral infections continue to cause morbidity and mortality in susceptible individuals worldwide. Hepatitis viruses continue to constitute a significant global health threat that results in substantial morbidity and mortality; Herpesviruses lead to significant health challenges, notably through conditions like herpes, varicella, zoster, mononucleosis, and various cancers including Kaposi’s sarcoma, nasopharyngeal carcinoma, and lymphoma. This book provides valuable insights for designing next-generation monoclonal antibodies.

**Order the printed version and SAVE 50% on the e-book with Print+eBook**

Table of Contents

Preface

Chapter 1. Monoclonal Antibody Development Technology for Important Human Diseases
Linlin Zhai and Chenguang Shen
BSL-3 Laboratory (Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, People’s Republic of China

Chapter 2.
Delivery and Therapeutic Application of Neutralizing Antibodies
Qi Li¹, Haonan Xing², Aiping Zheng², Yuanyu Huang¹, and Mei Lu¹
¹Advanced Research Institute of Multidisciplinary Science, School of Life Science, School of Medical Technology, Key Laboratory of Molecular Medicine and Biotherapy, Key Laboratory of Medical Molecule Science and Pharmaceutics Engineering, Beijing Institute of Technology, Zhongguancun, Beijing, China
²State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, China

Chapter 3. Neutralizing Antibodies against Enterovirus: Recent Advances and Future Challenges
Longfa Xu, Rui Zhu, and Tong Cheng
State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, School of Life Sciences, Xiamen University, Xiamen, PR China; Xiang An Biomedicine Laboratory, Xiamen, China; Research Unit of Frontier Technology of Structural Vaccinology, Chinese Academy of Medical Sciences, Xiamen Fujian, China

Chapter 4. Neutralizing Antibodies against Herpesvirus Entry Complex and Fusogen
Ling Zhong¹,², Wanlin Zhang¹,², Claude Krummenacher³, Qinjian Zhao¹, and Xiao Zhang¹
¹College of Pharmacy, Chongqing Medical University, Chongqing, PR China
²State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Experimental Research, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, PR China
³Department of Biological and Biomedical Sciences, Rowan University, Glassboro, NJ, USA

Chapter 5. Recent Advances in Hepatitis Virus Neutralizing Antibody Research
Mengyuan Zhao and Minghui Yang
School of Life Science, Advanced Research Institute of Multidisciplinary Science, Key Laboratory of Molecular Medicine and Biotherapy, Beijing Institute of Technology, Beijing, People’s Republic of China

Chapter 6. Research Progress on Neutralizing Antibodies against Orthopoxvirus:
Insights for Monkeypox Prevention and Treatment
Mengjun Li and Chenguang Shen
BSL-3 Laboratory (Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, People’s Republic of China

Chapter 7. Development of Anti-SARS-CoV-2 Neutralizing Antibodies
Yushan Jiang, Zihan He, Zhuolin Li, and Chenguang Shen
BSL-3 Laboratory (Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, People’s Republic of China

Chapter 8. A Possible Treatment Option for COVID-19: The Inflammatory Factor Antibodies
Jiayang Wang and Chenguang Shen
BSL-3 Laboratory (Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, People’s Republic of China

Chapter 9.
Nanobodies in Human Infectious Diseases: A Comprehensive Review of Research
and Applications
Ziyou Chen¹,², Yuanzhi Chen¹,², Zhiren Zeng¹,², Na Yuan¹,², Yaxian Mei¹,³, Zhenzhen Zhu¹,², and Wenxin Luo¹,²
¹State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics; National Institute of Diagnostics and Vaccine, Development in Infectious Diseases, School of Public Health, School of Life Sciences, Xiamen University, Xiamen, China
²Xiang Na Biomedicine Laboratory, Xiamen, China
³Brand Innovation Department, Hangzhou Innovax Biotech Co. Ltd, Hangzhou, Zhejiang, China

Index

Publish with Nova Science Publishers

We publish over 800 titles annually by leading researchers from around the world. Submit a Book Proposal Now!